Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: pregnant (230), expectant (11)

NIHR RTB_IBHO_PIS-ICF_v1.4_12SEP2024_Localised

Description: PARTICIPANT INFORMATION SHEET Improving Black Health Outcomes (IBHO) NIHR BioResource Version 1.4, 12 Sep 2024 Reading time: 20 minutes This
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-IBHO-PIS-ICF-v1.4-12SEP2024-Localised.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Using water for labour and birth - patient information

Description: We have given you this factsheet because you may be considering using water during the labour and birth of your baby
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Using-water-for-labour-and-birth-1681-PIL.pdf

Carboplatin(AUC6)-Paclitaxel-Pembrolizumab

Description: Chemotherapy Protocol LUNG CANCER CARBOPLATIN (AUC6)-PACLITAXEL-PEMBROLIZUMAB Regimen • Lung-Carboplatin (AUC6)-Paclitaxel-Pembrolizumab Indication - The patient has a histologically- or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinAUC6-Paclitaxel-Pembrolizumab.pdf

Carboplatin-Pembrolizumab-Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC 5)-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Carboplatin (AUC5)-Pembrolizumab-Pemetrexed Indication • Pembrolizumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pembrolizumab-Pemetrexed.pdf

UHS Inclusion and Belonging Strategy

Description: Our strategy sets out clear actions we will take to make UHS a place where every person feels they belong and
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/uhs-inclusion-and-belonging-strategy.pdf

WDES annual report 2022

Description: Workforce Disability Equality Standard - Annual Report 2022 2 Executive Summary The Workforce Disability Equality Standard (WDES) is a set of te
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Workforce-Disability-Equality-Standard-Annual-Report-2022.docx

Papers Council of Governors 25 January 2023

Description: Agenda attachments 1 CoG Agenda - 25.01.2023.docx Date Time Location Chair Agenda Council of Governors 25/01/2023 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-25-Jan-2023.pdf

Cisplatin-Pembrolizumab-Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Cisplatin-Pembrolizumab-Pemetrexed Indication • Pembrolizumab in combination with
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Cisplatin-Pembrolizumab-Pemetrexed.pdf

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

621 to 630 of 634

Previous … 60 61 62 63 64 Next